Tiragolumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | RG6058, MTIG7192A |
| Routes of administration | Intravenous |
| Drug class | Immune checkpoint inhibitor |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
| ChEBI | |
| Chemical and physical data | |
| Formula | C6620H10206N1742O2074S40 |
| Molar mass | 148664.99 g·mol−1 |
Tiragolumab (development names RG6058 and MTIG7192A) is a humanized monoclonal antibody that functions as an immune checkpoint inhibitor by targeting the T-cell immunoreceptor with Ig and ITIM domains (TIGIT) pathway.[1][2] Developed by Genentech and Roche, the drug is designed to enhance anti-tumor immune responses when used in combination with other immunotherapy agents, particularly atezolizumab (Tecentriq).[1]
In January 2021, tiragolumab received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for use in combination with atezolizumab in the treatment of patients with PD-L1-high metastatic non-small-cell lung cancer (NSCLC) who do not harbor EGFR mutations or ALK rearrangements.[3]
- ^ a b "Roche's novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer". www.roche.com. Archived from the original on 3 May 2025. Retrieved 21 July 2025.
- ^ "Tiragolumab (anti-TIGIT) Immunology & Inflammation related inhibitor | Read Reviews & Product Use Citations". www.selleckchem.com. Archived from the original on 22 December 2024. Retrieved 21 July 2025.
- ^ Rosa K (5 January 2021). "FDA Grants Breakthrough Therapy Designation to Tiragolumab Plus Atezolizumab for PD-L1–High NSCLC". OncLive. Archived from the original on 3 May 2025. Retrieved 21 July 2025.